APCS and primary systemic amyloidosis: Ourdrug CPHPC (Pepys et al., 2002) whichproduces persistent 90-99% depletion of circulating human SAP for as long as it isadministered, has led to no functional deficit or detectable adverse effect in 31adults with systemic amyloidosis treated for up to 7 years(Gillmore et al., 2010).